T1	Participants 82 125	patients with benign prostatic hyperplasia.
T2	Participants 126 154	Beta-sitosterol Study Group.
T3	Participants 449 627	randomised, double-blind, placebo-controlled multicentre study, 200 patients (recruited between April and October 1993) with symptomatic benign prostatic hyperplasia were treated
